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ABSTRACT 
The purposes of this study were to review utilization of 
insulin therapy in type 2 diabetes mellitus out patients and identify 
its Drug Related Problems (DRP). The data were collected cross-
sectionally with purposive sampling method in the period March 
2016 until May 2016 in Outpatient Clinic of Teaching Hospital 
Universitas Airlangga Surabaya. The results of 240 patients 
showed that insulin was used as monotherapy (insulin) in 2.9% 
patients; combination 1 insulin & 1-4 OAD in 31.3%; basal bolus 
therapy 27.9%; combination basal-bolus therapy & 1-3 OAD 
43.9%. Based on blood glucose target achievement, only 20.8% 
of patients achieve the target, 75.1% failed to achieve the target 
and 4.1% suffered from hypoglycemia. DRP identified adverse 
drug reaction of antidiabetic therapy such as hypoglycemia 
(6.7%), nausea (3.8%), bloating (1.3%), increase of flatulency 
(2.9%) and inappropriate combination (0.4%) were observed. In 
conclusion insulin therapy was complicated and individually, most 
of the patients still did not achieve the target and there was 
potential DRP in this patients group. Therefore caring from solid 
inter-professional health collaboration is needed. 
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INTRODUCTION  
Diabetes Mellitus (DM) is one of the 
major worldwide health problems, the 
incidence of DM has exhibited epidemic 
conditions (Barret et al., 2012). Global study 
data showed that DM patients in 2013 has 
reached 382 million people and is estimated  
the increase to 592 million by 2035. In 2012, 
5.1 million people in the age of 20 to 79 died of 
diabetes, which is equivalent to one death every 
six seconds is caused by diabetes and nearly 
half (48%) of them are under 60 years old 
(IDF, 2013). In 2013, diabetic patients in 
Indonesia had reached 8.5 million people (IDF, 
2013), whereas in East Java, it was estimated up 
to 2.1% (RIKESDAS, 2013).  
Type 2 DM requires intensive therapy 
management to prevent its progressivity and 
complications. The principal of management 
therapy in Type 2 DM included non-drug 
therapy-healthy lifestyle and drug therapy i.e. 
oral antidiabetic (OAD) either single or in 
combination with insulin (Suastika et al., 2011). 
When blood glucose levels remain 
uncontrolled, the OAD administration is 
stopped and the therapy is switched to               
insulin intensively (Ndraha, 2014). Early 
initiation of insulin therapy shows better 
clinical outcomes primarily related to 
glucotoxicity (Suastika et al., 2011). In addition, 
according to a study by UKPDS 35, the early 
insulin therapy in Type 2 DM intensively 
showed a decrease in morbidity or mortality 
(Soewondo et al, 2010). 
Initiation of insulin therapy in patients 
with type 2 diabetes could be conducted in 
patients who fail oral antidiabetic therapy 
(OAD), has poor blood glucose control (A1C> 
7.5% or fasting blood glucose ˃250mg/dL), 
with history of pancreatomy or pancreatic 
dysfunction, history of fluctuations in blood 
glucose levels, history of ketoacidosis, and 
experienced of DM over 10 years (Rismayanthi, 
2010). In addition, insulin therapy is also given 
to patients with type 2 DM who have some 
comorbid such as chronic hepatitis, pulmonary 
tuberculosis, fractures, cancer, cellulitis/ 
gangrene, graves’ disease and severe hepatic 
disorders (Pranoto, 2012). This study aims to 
review the use of insulin therapy in type 2 DM 
patients and identification of drug-related 
problems in these patients. 
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MATERIAL AND METHODS 
This is an observational and cross-
sectional study conducted at the Out-patient 
Clinic Universitas Airlangga Teaching Hospital 
in Surabaya, Indonesia. Inclusion criteria were 
Type 2 DM patients undergoing therapy using 
insulin or insulin-OAD (Oral Anti Diabetic) 
combination. The data were collected from 
March to May 2016. The sampling was 
obtained by purposive sampling method until 
the sample number was fulfilling. Descriptive 
analysis was conducted for the patient's insulin 
therapy profile, achievement of blood sugar 
target and problems that are related to anti-
diabetic. 
 
RESULT AND DISCUSSION 
From 240 patients obtained there were 
127 (52.9%) female patients which was higher 
than male patients, 113 (47.1%). This aligned 
with the International Diabetes Federation data 
that shows the prevalence of DM patients in 
Indonesia is higher in women, that is 57.73% 
(IDF, 2013). The higher prevalence of Type 2 
DM patients in women is associated with lower 
physical activity and more obesity conditions 
experienced by women (WHO, 2016). 
Based on age distribution, it shows that 
more patients in the age of the 45-54 years 
there were (25.8%) and 55-64 years (41.2%) 
(Table I). This is in accordance with the 
research conducted by the Center for Disease 
Control and Prevention, which shows that 
most people with Type 2 DM are in the age 
range of 45-64 years (CDC, 2015), where at age 
˃ 45 years the insulin resistance increase and 
impaired function of pancreatic cells (Kyung et 
al., 2016). The impaired of pancreatic cell 
function causes a decrease in the capacity of 
proliferative islet cells resulting in a decrease in 
insulin production (Kirkman et al., 2012). 
However, in this study there were 7.5% of 
patients in the age of <45 years and there was 
one patient (0.4%) at the age of 25 years old. 
Research conducted by the Ministry of Health 
of the Republic of Indonesia in 2013 showed 
that 9.90% of patients with Type 2 DM is at the 
age <45 years (RISKESDAS, 2013). This 
indicates that incidence of Type 2 DM is 
increasing among young people. Lifestyle and 
obesity is the main factors suspected to be the 
cause of Type 2 DM. In addition, genetic 
factors, gestational diabetes and lack of physical 
activity during childhood and adolescence lead 
to an increase in insulin resistance that triggers 
the onset of Type 2 DM among young people 
(Bloomgarden, 2004). 
In Type 2 DM patients may be 
accompanied by various microvascular and 
macrovascular and comorbid complications 
(Table I). In this study the most complication 
experienced was nephropathy 24.2% and 
comorbid was hypertension 62.9%. Diabetic 
nephropathy is a microvascular complication 
characterized by hyperfiltration of the 
glomerular basement membrane (Funk, 2014). 
The pathogenesis of diabetic nephropathy may 
be an increase in AGEs product that causes 
damage to the renal glomerulus. In addition, 
polyol pathway increases sorbitol and decreases 
inositol levels causing impaired basement 
membrane osmolarity (Bennett and Bhardari, 
2015). While, in this study 62.9% patients with 
hypertension. Hypertension is a risk factor for 
DM (ADA, 2015), in the other hand 
hypertension is one complication of DM. A 
hyperglycemia conditions cause glucose to react 
non-enzymatically with free amino acids of the 
body membrane, produce AGEs product that 
will cause damage the organs and blood vessel 
network as well as the formation of 
arteriosclerosis that causes narrowing of artery 
walls (Funk, 2014). 
According to PERKENI, at the 
beginning of therapy Type 2 DM can be used 
OAD monotherapy. If blood glucose has not 
been controlled with OAD monotherapy use a 
combination of 2 OAD with a different 
mechanism. If on 2 OAD combinations blood 
glucose still uncontrollable a combination of 3 
OAD or a combination of 2 OAD can be used 
together with basal insulin. If on this 
combination blood glucose remains 
uncontrolled, then the OAD is stopped and the 
therapy switches to insulin intensively 
(PERKENI, 2011). The European Association 
for the Study of Diabetes (EASD) recommends 
the more aggressive type 2 DM therapy that 
after the first step with lifestyle intervention 
and metformin is unsuccessful, the next            
step can be started by administering insulin. 
Early  insulin initiation provides better glycemic  
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control,   improves   HbA1C   and   inhibits the  
progressivity of decreased pancreatic β cell 
function (Meneghini, 2009; Inzucchi et al., 
2015). In addition, according to a study by 
UKPDS 35, the use of early insulin therapy in 
Type 2 DM intensively showed decreased 
morbidity or mortality (Soewondo et al, 2010). 
The profiles of antidiabetic, insulin and OAD 
use were shown in Figure 1, single insulin 
therapy (2.9%), a combination of 1 insulin and 
OAD (31.3%), basal-bolus combination 
(27.9%), and combination basal bolus insulin-
OAD (37.9%).  
The types of antidiabetic used were 
rapid-acting insulin (aspart, glulisine), long-
acting insulin (glargine, determir) and mixed 
insulin (70/30 protamine aspart/aspart and 
75/25 protamine lispro/lispro) subcutaneously, 
and sulfonylureas, biguanides, thiazolidinedione 
and  ɑ-glucosidase   inhibitors orally  (Table II). 
Tabel I. Characteristic of Type 2 DM Patients in Out Patients Clinic Universitas Airlangga 
Teaching Hospital Surabaya Indonesia 
 
No.  Characteristic Number of patients (%) 
1 Gender Male 
Female 
113 (47,1) 
127 (52.9) 
2 Age (year) 25-34 
35-44 
45-54 
55-64 
65-74 
>75 
1 (0.4) 
18 (7.7) 
62 (25.8) 
99 (41.2) 
46 (19.2) 
14 (5.8) 
3 Complication Nephropathy 
Neuropathy 
Retinopathy 
Coronary Artery Disease 
Stroke 
Ulcus Pedis 
Gangrene 
Chronic Kidney Disease 
58 (24.2) 
20 (8.3) 
1 (0.4) 
5 (2.1) 
4 (1.7) 
2 (0.8) 
2 (0.8) 
4 (1.7) 
4 Comorbid Hypertension* 
Dyslipidemia 
Dyspepsia 
Hypertoroid 
Hyperuricemia 
Osteoarthritis 
Heart failure 
Hepatic Cirrhosis 
Ascites 
Frozen shoulder 
Acute Respiratory infection 
Anemia 
Cholelithiasis (Batu empedu) 
Low Back Pain (LBP) 
Benign Prostate Hyperplasia (BPH) 
Asthma 
Vertigo, Cephalgia 
151 (62.9) 
102 (42.5) 
16 (6.7) 
1 (0.4) 
31 (12.9) 
9 (3.7) 
3 (1.2) 
1 (0.4) 
1(0.4) 
1 (0.4) 
5 (2.1) 
1 (0.4) 
4 (1.7) 
1(0.4) 
3 (1..2) 
2 (.8) 
3 (1.2) 
 
Note:, A patient could have more than one complication and comorbid; Percentage to total patient (240 
patient); (*) Hypertension not known it is DM complication or comorbid. So in this study HT classified into 
comorbid. 
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Long-acting insulin is most widely used, 
72.50% of the total patient. The use of long-
acting insulin in patients with Type 2 DM is to 
cover basal insulin needs (Schwinghammer, 
2015). The most widely used long-acting insulin 
is glargine, 43.75%, an insulin analog that has a 
long acting and peakless. Insulin glargine has a 
slow onset of action (1-1.5h) and give maximum 
effect after 4-6h, the activity is maintained for 
11-24h or more. Insulin glargine is a clear liquid 
insulin with a pH of 4, after subcutaneous 
injection will form micro- precipitation in so 
that release slowly (Schwinghammer, 2015). 
Another long-acting insulin applied is detemir. 
Detemir insulin has an onset of action 1-2h and 
a duration of  action about 24h (Kennedy and 
Masharani, 2015). In detemir insulin, the C14 
fatty acids are bound to albumin, causes slow 
release (Schwinghammer, 2015). Administration 
long-acting insulin can be given in the morning 
or evening. In this study long-acting insulin 
79.89% was administered at night. The use of 
basal insulin at night can significantly reduce 
the production of basal glucose hepar in order 
to provide better glycemic control (Pranoto, 
2012). 
 
 
Figure 1. Profile of antidiabetic therapy in out patients clinic universitas 
 
Tabel II. Type of antidiabetes used in in out patients clinic Universitas Airlangga Teaching Hospital 
Surabaya Iherapy  
 
Class Name Frequency 
Total patients in 
each class (%) 
Insulin 
Rapid-acting 
 
Aspart   
Glulisine  
81 (33.75) 
19 (7.92) 100 (41.7) 
Long-acting Glargine 
Detemir  
105 (43.75) 
174 (72.5) 
69 (28.75) 
Mixed - 70/30 Protamine Aspart/ Aspart  
- 75/25 Protamine Lispro/ Lispro  
58 (24.17) 
4 (1.67) 62 (25.8) 
OAD 
Biguanida Metformin  102 (42.50) 102 (42.5) 
Sulfonilurea Glimepirid  
Gliclazid  
Glikuidon  
70 (29.17) 
10 (4.17) 
9 (3.75) 
89 (37.1) 
Tiazolidinedione Pioglitazone  17 (7.08) 17 (7.1) 
ɑ-glukosidase 
inhibitor 
Acarbose  49 20.42) 
49 
(20.4) 
 
Note : A Patients could get more than one antidiabetes; Percentage to tatal patient (240 patient) 
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From 240 patients, 41.7% received rapid 
insulin therapy. The administration of rapid-
acting insulin aims to fulfill insulin needs at 
mealtime, because it has a shorter onset and 
shorter duration of action that mimics normal 
endogenous insulin secretion (Kennedy and 
Masharani, 2015). The most widely used type of 
rapid-acting insulin was aspart insulin 33.8%. 
Aspart insulin is an insulin analogous with the 
replacement of the B28 amino acid structure 
with aspartic acid (Tanyolac et al., 2010).             
This structural change causes rapid dissociation 
into monomer form when injected subcuta-
neously. The onset of action of insulin aspart is 
5-15min with a duration of action of 4-6h. 
Other rapid-acting insulin used is  glulisine 
insulin 7.9%. Glulisine insulin is an analogue 
insulin that replaces B3- amino acid asparagin 
with lysine and lysine at the B29 position is 
replaced with glutamic acid. The onset of 
action glulisine insulin is 15min with a duration 
of action about 5h (Tanwani, 2011). 
Mixed insulin (premixed insulin) 
contains long-acting insulin and rapid-acting 
insulin with a certain ratio in a dosage. The 
advantage of mixed insulin has a prandial and 
basal glycemic effect at once, thus it can 
provide longer glycemic control (Pranoto, 
2012). Type of mixed insulin used was 70/30 
Protamine Aspart/Aspart insulin (24.2%) and 
75/25 Protamine Lispro/Lispro insulin (1.7%). 
Onset of action 70/30 Protamine Aspart/ 
Aspart insulin is 10-20min with a duration of 
action 15-18h.  
According to the American Diabetes 
Association, the use of insulin in type 2 
diabetes can be started with long-acting insulin 
in the morning or before bedtime with an initial 
dose of 10U or 0.2U/kgBW (ADA, 2015). 
Titration was performed base on blood glucose 
monitoring, by increasing 2U doses every 3 
days until fasting blood glucose (FBG) reaches 
(70-130mg/dL), or it can be increased 4U or 
more if FBG> 180mg/dL. If there is a 
hypoglycemia or FBG <70mg/dL, dose 
decreased by 2-4U. The addition of rapid- 
acting insulin may be performed if 2h 
postprandial blood glucose (2PPBG) is                 
high, the initial dose usually begins with                
4U and adjusts 2U every 3 days until blood 
glucose is   within   the   target  range  (Nathan, 
2009).  
The dosage and frequency of insulin           
(Table III). In this study, the dose of             
long-acting insulin in the range 6- 50 units             
and rapid-acting insulin 4-32 units, while               
the mixed insulin dose is between 6-34 units             
in   the   morning   and   6-30   units   at   night.  
Table III. Dose and frequency of insulin administration 
 
Drug Name Insulin Dose  Frequency 
Aspart  4-26U 3x 
Glulisine 5-32U 3x 
Glargine  6-50U 1x 
Detemir  6-44U 1x 
70/30 Protamine Aspart/Aspart  
(6-30)-0-(6-28)U 
(30-34)-10-(28-30)U 
2x 
3x 
75/25 Protamine Lispro/Lispro  (12-24)-0-(10-20)U 2x 
 
Table IV. Time administration of long acting insulin 
 
Type of Long Acting Insulin 
Time of Administration 
Morning (%) Night (%) 
Glargine  19 86 
Detemir  16 53 
Total  35 (20.1) 139 (79.9) 
 
Note: Percentage of total patient who is got glargine or detemir (174 patient) 
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Table V. Use of Insulin and Insulin-OAD Combination 
 
Type of Regimen Agent Number of Patients (%) 
Single Insulin Rapid acting insulin 
Long acting insulin 
1 (0.4) 
6 (2.5) 
Total 7 (2.9) 
Type 1 combination  
(1 Insulin + 1 OAD) 
Long acting insulin + SU 
Long acting insulin + Big 
Rapid acting insulin + SU 
26 (10.7) 
1 (0.4) 
2 (0.8) 
Total 29 (12.1) 
Type 2 combination  
(1 Insulin + 2 OAD) 
Long act. Insulin+ AGI+SU 
Long act. Insulin+ Big +SU 
Long act. Insulin +TZD + SU 
Rapid act. Insulin + Big + SU 
7 (2.9) 
22 (9.2) 
3 (1.2) 
1 (0.4) 
Total 33 (13.7) 
Type 3 combination  
(1 Insulin + 3 OAD) 
Long act. insulin + AGI + SU + Big 
Long act. insulin + SU+Big+TZD 
11 (4.6) 
1 (0.4) 
Total 12 (5.0) 
Type 4 combination  
(1 Insulin + 4 OAD) 
Long act. Insulin + AGI + SU + Big + TZD 1 (0.4) 
Total 1 (0.4) 
Type 5 combination 
(Insulin Basal−Bolus) 
Rapid act. Insulin + Long act.insulin 
70/30 mix insulin 
75/25 mix insulin 
46 (19.2) 
19 (7.9) 
2 (0.8) 
Total 67 (27.9) 
Type 6 combination 
(Insulin Basal−Bolus 
+ 1 OAD) 
Rapid act. Insulin + long act. Insulin + AGI 
Rapid act. Insulin + long act. Insulin + Big 
Rapid act. Insulin + long act. Insulin + TZD 
70/30 Mix insulin + AGI 
70/30 Mix insulin + SU 
70/30 Mix insulin + Big 
70/30 Mix insulin + TZD 
75/25 Mix insulin + Big 
5 (2.1) 
14 (5.8) 
5 (2.1) 
8 (3.3) 
2 (0.8) 
13 (5.4) 
3 (1.2) 
1 (0.4) 
Total 61 (25.42) 
Type 7 combination 
(Insulin Basal−Bolus 
+ 2 OAD) 
Rapid act. Insulin + long act. Insulin + AGI + Big 
Rapid act. Insulin + long act. Insulin + SU + Big 
Rapid act. Insulin + long act. Insulin + Big + TZD 
Rapid act. Insulin + long act. Insulin + AGI + SU 
Rapid act. Insulin + long act. Insulin + AGI + TZD 
70/30 Mix Insulin + AGI + Big 
70/30 Mix Insulin + AGI + SU 
70/30 Mix Insulin + SU + Big 
70/30 Mix Insulin + Big + TZD 
75/25 Mix Insulin + SU + Big 
7 (2.9) 
10 (4.2) 
1 (0.4) 
1 (0.4) 
1 (0.4) 
1 (0.4) 
4 (1.7) 
2 (0.8) 
1 (0.4) 
1 (0.4) 
Total 29 (12.1) 
Type 8 combination 
(Insulin Basal−Bolus 
+ 
3 OAD) 
Rapid act. Insulin+long act. 
Insulin+AGI+Big+TZD 
1 (0.4) 
Total 1 (0.4) 
Total  240 (100.0) 
 
Note: Percentage to total patients (240 patient) 
SU: sulphonyl urea (Glimepiride, Gliclazide, Gliquidone), AGI: alpha glycosidase inhibitor (acarbose), Big: 
biguanide (metformin), TZD: Thiazolidindione (pioglitazon), Long act. Insulin (glargin, detemir), Rapid act. 
Insulin (aspart, glulisine), 70/30 Mix insulin (Protamin aspart/aspart), 75/25 Mix insulin (Protamin 
lispro/lispro) 
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It can be seen that the dose of insulin therapy is 
highly individual, due to the sensitivity of 
insulin receptors in each individual is different, 
the varying action of insulin in each individual 
(Boucher et al., 2014).  
The oral antidiabetic (OAD) used in this 
study were sulfonylureas (gliclazides, 
glimepirides, gliquidones), biguanides 
(metformin), α-glucosidase (acarbose) and 
thiazolidinedione (pioglitazone) inhibitors. In 
this study, 37.1% of patients received 
sulfonylurea therapy, i.e. glimepiride (29.2%), 
gliclazide (4.2%), and gliquidone (3.8%). The 
UKPDS study showed that more than 50%           
of DM patients receiving sulfonylurea           
therapy required additional insulin therapy to 
achieve the glycemic target (Massi and Orsini, 
2008). The combination of glimepiride with 
insulin can lower uncontrolled blood glucose 
levels (Funk, 2014). However, in the 
combination of insulin and sulfonylurea, 
patient’s blood glucose levels should be 
monitored, considering that both drugs are 
synergistic in lowering blood glucose levels, 
which can increase the risk of hypoglycemia 
(Raccah et al., 2007).  
Tabel VII. Post prandial blood glucose (2PPBG) and bolusi insulin adjustment (Rapid acting 
Insulin) 
  
2PPBG(mg/dL) Dose Adjustment Number of Patients (%) Total Patients (%) 
<100 
Dose reduce 
No change 
1(1.10) 
2(2.20) 
3(3.3) 
100-199 
No change 
Dose reduce 
26(28.57) 
6(1.10) 
32(35.2) 
200-299 
Dose reduce 
No Change 
Dose Increase  
1(1.10) 
20(21.98) 
13(7.69) 
34(37.4) 
300-399 
No Change 
Dose increase 
7(7.69) 
8(3.30) 
15(16.5) 
400-499 
No change 
Dose increase 
1(1.10) 
4(2.20) 
5(5.5) 
500-599 Dose increase 2(1.10) 2(2.2) 
 
Note: Total patient = 91 with 2PPBG 
 
Tabel VIII. Blood glucose achievement 
 
 Blood Glucose Level* Number of Patients Total (%) 
 Hypoglycemia** (GDP <80mg/dL) 9 9 (4.1) 
Achieved the target 
 
- FBG 80-130mg/dL 
- 2PPBG <180mg/dL 
- RBG < 200mg/Dl 
46  46 (20.8) 
Not Achieved the Target 
 
- FBG >130 mg/dL 
- 2PPBG >180mg/dL 
- RBG ≥200mg/dL 
110 
166 (75.1) 
FBG achieved 
 
- FBG 80-130mg/dL 
- 2PP BG Not Achieved  
- 2PPBG >180mg/dL 
37 
FBG Not Achieved 
 
- FBG>130mg/dL 
- 2PPBG Achieved 
- 2PPBG <180mg/dL 
19 
 Total 221 (100.00) 
 
Note: BG achievement was outcome of achievement one month therapy before; Total patient 221, there is 
no BG data in 19 patient; (*) ADA, 2015; (**) Hypoglycemia is indicated by FBG <80mg/dL 
(PERMENKES No. 5 Tahun 2014). 
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In this study, 42.5% of patients received 
metformin therapy. Metformin is recommended 
as first-line therapy for Type 2 diabetes, 
because it increases insulin sensitivity and not 
increase weight or cause hypoglycemia. Beside 
that metformin has lowering effect on cholesterol, 
free fatty acids and triglycerides, so that improved 
lipid profiles and inhibit the occurrence of 
macrovascular and microvascular complications 
(Hundal and Inzucchi, 2003), but this drug is 
contraindicated in patients with renal impairment, 
liver disease, hypoxia, and a history of lactic 
acidosis (Kroon and Williams, 2013). A total of 
20.4% of patients received acarbose, an oral 
antidiabetic that acts by inhibiting the ɑ-
glucosidase enzyme found in the small intestine 
wall, reduces postprandial glucose levels in 
Type 2 DM patients (Schwinghammer, 2015). 
This drug has a low risk of hypoglycemia (Li 
Feng-fei et al., 2015). A total of 7.1% of patients 
received pioglitazone, that has effect in 
lowering insulin resistance by increasing the 
amount of glucose transporter. In patients with 
type 2 DM with dyslipidemia, a thiazolidine-
dione can improve lipid profile. Research 
conducted by Ghazzi showed that thiazolidine-
dione (pioglitazone) decrease triglyceride levels 
and increase HDL levels in Type 2 DM 
patients. However, the influence of thiazolidine-
dione on lipids is not enough to replace statins 
as dyslipidemia therapy (Ismail, 2004). 
Several studies have shown that intensive 
glycemic control can be achieved by 
combination therapy (Massi and Orsini, 2008). 
It has been stated that combination of insulin 
and OAD results better in glycemic control 
compared to single insulin use (Pranoto, 2011). 
The advantage of this combination can reduce 
the required dose of insulin, decrease the 
number of injections, ease insulin dose titration 
and improve adherence (Massi and Orsini, 
2008). 
In this study, 30.8% of patients received 
insulin therapy (single or basal-bolus) and 
69.2% of patients receiving OAD-insulin 
combination therapy. The combination of 
insulin-OAD therapy is very diverse, ranging 
from a combination of 1-2 of insulin types and 
1-4 of oral antidiabetic (Table 5). Basal-bolus 
therapy is given when blood glucose and 
HbA1C levels were still uncontrolled with 
combination therapy of basal insulin and OAD 
(Harper et al., 2013), the addition of prandial 
insulin improves overall glycemic control 
(Umpierrez et al., 2007). Prandial insulin is 
given at an initial dose of 6U or 0.1/kgBW and 
administered before each meal. 
In this study, it was found that several 
inappropriate combinations of therapy were 
not in accordance with the protocol, such as 
the combination of rapid-acting insulin (bolus 
insulin) with sulfonylurea groups, which may 
increase the risk of hypoglycemia. Oral insulin 
secretagogin (sulfonylurea) should be 
discontinued if prandial insulin is given (Raccah 
et al., 2007; Pranoto, 2012). In addition, there 
was an inappropriate combination of long-
acting insulin with 4 types of oral antidiabetic 
(Type 4 Combination). This combination was 
not appropriate. According to PERKENI, if 
the patients receive the combination therapy of 
basal insulin and OAD but the blood glucose is 
still uncontrolled, then the therapy has to stop 
and shift to insulin intensively (basal-bolus 
therapy) (PERKENI, 2011). It is in line with 
the recommendation of the American Diabetes 
Association, if the patient's HbA1C target is 
not achieved for 3 months with triple therapy 
or combination of basal insulin and 2 OAD, it 
is recommended to switch to basal-bolus 
therapy (ADA, 2015). 
The dosage and frequency of antidiabetic 
use in type 2 diabetes mellitus therapy are 
highly dependent on patient’s condition that 
includes blood glucose level, HbA1C value, 
complication and comorbid, and patient 
compliance. Blood glucose levels (FBG and 
2PPBG) are indicators of patient glycemic level 
controls. Dose adjustment of long-acting 
insulin was based on FBG, while rapid-acting 
insulin dose is adjusted to 2PPBG (ADA, 
2015). In Table VI showed the value patient’s 
fasting blood glucose (FBG) levels and its basal 
insulin therapy. Patients with FBG <70 mg/dL 
(2.3%) had hypoglycemic conditions, so it was 
recommended to decrease the insulin dose by 
2-4U (Nathan, 2009). Patients with FBG 70-
130 mg/dL (37.8%) is recommended to 
maintain the dose, but in this study there was 
an increase insulin dose by 2-6 U, this was due 
to blood glucose levels still reaches the upper 
limit  of the glycemic target and the patient  has  
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a high 2PPBG level. The addition of a basal 
insulin dose may be lowering the patient's 
2PPBG levels (Rakel et al., 2015). In some 
patients there was a dose reduction of 2-8 U 
because the patient has a risk of hypoglycemia 
or experienced hypoglycemia. Patients with 
GDP >130 mg/dL (30%) and GDP >180 
mg/dL (30%) were recommended for the 
addition of 2-4U insulin, but 31.3% of patients 
with high GDP levels were not added insulin 
because there is significant BG decrease from 
previous therapy. The simillar reason use for 
insulin adjustmen 2PPBG. 
Many aspects must be considered in 
determining the patient's glycemic target. The 
recommended glycemic target by the American 
Association Diabetes is the optimal target, but 
the glycemic target is individualized and tailored 
to the needs of each patient (ADA, 2015). 
Factors to be considered for the determination 
of glycemic targets in patients with type 2 
diabetes include age or life expectancy, 
comorbidity, duration of diabetes, the risk of 
hypoglycemia, and presence of microvascular 
complications (ADA, 2015). 
Blood glucose target is achieved if FBG 
is in the range 80-130 mg/dL and 2PPBG 
<180 mg/dL (ADA, 2015). This study showed 
of 240 patients with Type 2 DM there were 19 
patients who did not have blood glucose levels 
at the time of observation, so that the blood 
glucose level was obtained from 221 patients. 
Of the 221 patients, 20.8% patients achieved 
BG target, while 75.1% patients did not achieve 
blood glucose target. It showed that blood 
glucose controled in these patients is not easy. 
These patients were referral patients from first 
health services, sent to hospital as higher 
second health  services cause they had 
uncontrolled blood glucose or had DM 
complication. As blood glucose or complication 
has been controlled this patients would be 
referred back to first health services. Previous 
study in type 2 DM geriatric patients showed 
blood glucose target was achieved in 53% 
patients (Suprapti et al, 2014).  
A total of 4.1% of patients had 
hypoglycemic conditions, characterized by 
FBG level <80 mg/dL. According to the ADA, 
the condition of hypoglycemia is characterized 
by blood glucose levels <70 mg/dL, but criteria 
for hypoglycemia in the clinic is characterized 
by blood glucose <80 mg/dL, this is done 
because the hypoglycemia condition is 
dangerous and life-threatening, so that higher 
values are used for the purpose of patient 
safety. It also complies with PERMENKES 
No.5, 2014 on the Clinical Practice Guidelines 
for Physicians, which explains that 
hypoglycemia is characterized by blood glucose 
levels <80 mg/dL (PERMENKES RI, 2014). 
Side effects of insulin found in this study 
were hypoglycemia. A total of 6.7% of patients 
had hypoglycemia and were identified to 
receive insulin or sulfonylurea therapy. 
Potential side effects of insulin and sulfonylurea 
use are hypoglycemia (Kennedy & Masharani, 
2015). Hypoglycemia is shown in the presence 
of complaints such as shaking, cold sweat, 
dizziness, weakness and palpitations. Patients 
with hypoglycemia usually result from overly 
high doses of insulin, inadequate dietary intake 
(delayed, skipped meal, little intake), fasting 
conditions, excessive activity. Other DRP 
found were an inappropriate combination, i.e. 
the combination of rapid-acting insulin with 
sulfonylurea group OAD (3.8%), and a 
combination of 1 insulin with 4 OAD (0,4%). 
 
CONCLUSION 
In conclusion insulin therapies were 
complicated and individually, most of the 
patients still did not reach the target and there 
was potential drug related problem in this 
patients group. So that caring from solid 
interprofesional health collaboration is nedeed. 
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